Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Delivery
Return to: PBR Home | Drug Research | Drug Delivery

Drug Delivery

GeoVax secures NIH grant for HIV vaccine program By PBR Staff Writer
US-based biotechnology firm GeoVax Labs has received a notice of award from the US National Institutes of Health (NIH) for a small business innovative research (SBIR) grant in support of its clade C HIV vaccine development program for Africa.
Drug Research > Drug Delivery > News
Novo Nordisk to stop distribution of diabetes drug Tresiba in Germany By PBR Staff Writer
Danish pharmaceutical firm Novo Nordisk has decided to stop distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany.
Drug Research > Drug Delivery > News Cellular Biomedicine completes acquisition of CD40LGVAX vaccine Cellular Biomedicine Group (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced it has completed the previously announced acquisition of Blackbird Bio Finance and University of South Florida's (Licensor) next generation GVAX vaccine's (CD40LGVAX) related technologies and technical knowledge.
Drug Research > Drug Delivery > News
See more Drug Delivery news

Latest Drug Delivery News and Insight

View all Drug Delivery news or find news targeted to your interests
Immunovaccine begins Phase I trial with DPX-RSV vaccine
Immunovaccine, a clinical stage vaccine and immunotherapy company, announced that it has enrolled the first healthy adult volunteer in a Phase I clinical study of its respiratory syncytial virus (RSV) vaccine.
Drug Research > Drug Delivery > News
Bayer's Eylea gets approval in Japan to treat retinal vein occlusion
By PBR Staff Writer
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Bayer HealthCare's Eylea (aflibercept solution for injection) to treat patients with macular edema secondary to retinal vein occlusion (RVO).
Drug Research > Drug Delivery > News
Siemens, BioNTech to develop new personalized cancer vaccines
By PBR Staff Writer
Siemens has entered into a strategic collaboration with BioNTech for the good manufacturing practice (GMP) production of personalized cancer vaccines.
Drug Research > Drug Delivery > News
Protein Sciences reports positive results from new clinical study of Flublok influenza vaccine
Protein Sciences announced topline data showing that Flublok Quadrivalent – the quadrivalent version of FDA-approved trivalent Flublok influenza vaccine – outperformed a traditional influenza vaccine last season and was better at preventing the flu.
Drug Research > Drug Delivery > News
Pfizer begins patient enrollment in Phase III trial of rivipansel to treat vaso-occlusive crisis
By PBR Staff Writer
Pfizer has started patient enrollment in the Phase III clinical trial (RESET) evaluating the efficacy and safety of rivipansel, an investigational pan-selectin inhibitor, to treat vaso-occlusive crisis in hospitalized individuals with sickle cell disease (SCD) who are six years of age or older.
Drug Research > Drug Delivery > News
Vaxil's ImMucin gets FDA orphan drug status to treat multiple myeloma
Vaxil Bio, a company specializing in the development of immunotherapy-based drugs, reports that its lead product, ImMucin, has been granted an 'orphan drug' designation by the US Food and Drug Administration (FDA), for the treatment of multiple myeloma (MM).
Drug Research > Drug Delivery > News
Vical reports top-line results from Phase I/II trial of therapeutic genital herpes vaccine
Vical Incorporated announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase I/II clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients.
Drug Research > Drug Delivery > News
FDA approves Medicines Company's kengreal as adjunct to PCI to reduce thrombotic events
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved Medicines Company's Kengreal (cangrelor) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).
Drug Research > Drug Delivery > News
Pfizer agrees to buy GSK's two meningitis vaccines for $130m
By PBR Staff Writer
Pfizer has entered into an agreement to acquire two meningitis vaccines from GlaxoSmithKline for about $130m in order to expand its global reach in preventing meningococcal disease.
Drug Research > Drug Delivery > News
Impax's Zomig nasal spray gets FDA approval to treat migraine in pediatric patients
By PBR Staff Writer
Impax Specialty Pharma has received approval from the US Food and Drug Administration (FDA) for Zomig Nasal Spray for use in pediatric patients aged 12 years of age and older for the acute treatment of migraine with or without aura.
Drug Research > Drug Delivery > News
View all Drug Delivery news or find news targeted to your interests